Compare McKesson Corporation (MCK) vs Spotify Technology (SPOT) Price & Performance

McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.

MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.

Spotify (SPOT) trades at $512.92, up 5.08% with strong bullish technical signals from moving averages. The company demonstrates robust fundamental momentum with revenue growing from $11.7B in 2022 to $17.2B in 2025, while achieving profitability with net income reaching $2.2B. Recent earnings show mixed results with Q2 2026 missing expectations, but analyst consensus remains overwhelmingly positive with 62% buy ratings and a $608.18 price target representing 19% upside potential.

The outlook remains favorable with projected 2026 revenue of $18.1B and net income of $3.3B, though risks include competitive pressures in streaming and recent stock volatility. Key catalysts include Q3 2026 earnings release on October 22, 2026, and continued gross margin expansion from 32.8% currently. Institutional sentiment appears constructive given the strong buy-side analyst coverage and improving cash flow trends.